Medicamen Biotech Limited (NSE:MEDICAMEQ)
India
· Delayed Price · Currency is INR 415.00
-6.60 (-1.57%)
Jun 27, 2025, 3:29 PM IST
Medicamen Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 1,603 | 1,779 | 1,404 | 1,083 | 1,107 | Upgrade
|
Other Revenue | 22.21 | 14.26 | 4.58 | 71.55 | 19.94 | Upgrade
|
| 1,625 | 1,793 | 1,409 | 1,154 | 1,127 | Upgrade
| |
Revenue Growth (YoY) | -9.35% | 27.29% | 22.02% | 2.42% | -10.21% | Upgrade
|
Cost of Revenue | 846.18 | 941.05 | 734.49 | 542.07 | 710.91 | Upgrade
|
Gross Profit | 779.29 | 852.01 | 674.19 | 612.38 | 416.25 | Upgrade
|
Selling, General & Admin | 321.68 | 335.17 | 218.24 | 155.56 | 95.99 | Upgrade
|
Other Operating Expenses | 319.03 | 293.34 | 215.96 | 220.16 | 126.81 | Upgrade
|
Operating Expenses | 711.37 | 699.44 | 497.86 | 433.43 | 248 | Upgrade
|
Operating Income | 67.92 | 152.57 | 176.32 | 178.96 | 168.25 | Upgrade
|
Interest Expense | -31.56 | -43.97 | -29.23 | -14.01 | -10.64 | Upgrade
|
Interest & Investment Income | - | 7.24 | 7.21 | 1.35 | 1.53 | Upgrade
|
Currency Exchange Gain (Loss) | - | 13.85 | 14.76 | 14.49 | 4.71 | Upgrade
|
Other Non Operating Income (Expenses) | 62.44 | 0.33 | 1.29 | 0.08 | 0.01 | Upgrade
|
EBT Excluding Unusual Items | 98.8 | 130.02 | 170.35 | 180.87 | 163.87 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | 0.02 | 0.04 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 0 | -0.07 | -0.01 | -0.01 | Upgrade
|
Pretax Income | 98.8 | 130.76 | 170.45 | 180.95 | 163.94 | Upgrade
|
Income Tax Expense | 33.24 | 35.82 | 23.17 | 31.97 | 42.65 | Upgrade
|
Earnings From Continuing Operations | 65.56 | 94.94 | 147.29 | 148.98 | 121.29 | Upgrade
|
Minority Interest in Earnings | 5.53 | 14.37 | 1.16 | - | - | Upgrade
|
Net Income | 71.08 | 109.31 | 148.44 | 148.98 | 121.29 | Upgrade
|
Net Income to Common | 71.08 | 109.31 | 148.44 | 148.98 | 121.29 | Upgrade
|
Net Income Growth | -34.97% | -26.36% | -0.36% | 22.82% | -8.74% | Upgrade
|
Shares Outstanding (Basic) | 13 | 13 | 13 | 12 | 12 | Upgrade
|
Shares Outstanding (Diluted) | 13 | 13 | 13 | 12 | 12 | Upgrade
|
Shares Change (YoY) | 0.44% | 0.07% | 3.56% | - | 0.56% | Upgrade
|
EPS (Basic) | 5.59 | 8.63 | 11.73 | 12.19 | 9.93 | Upgrade
|
EPS (Diluted) | 5.59 | 8.63 | 11.73 | 12.19 | 9.93 | Upgrade
|
EPS Growth | -35.25% | -26.41% | -3.78% | 22.82% | -9.24% | Upgrade
|
Free Cash Flow | -92.67 | -130.31 | -128.94 | -44.99 | -51.94 | Upgrade
|
Free Cash Flow Per Share | -7.29 | -10.29 | -10.19 | -3.68 | -4.25 | Upgrade
|
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | Upgrade
|
Dividend Growth | - | - | - | - | 100.00% | Upgrade
|
Gross Margin | 47.94% | 47.52% | 47.86% | 53.04% | 36.93% | Upgrade
|
Operating Margin | 4.18% | 8.51% | 12.52% | 15.50% | 14.93% | Upgrade
|
Profit Margin | 4.37% | 6.10% | 10.54% | 12.90% | 10.76% | Upgrade
|
Free Cash Flow Margin | -5.70% | -7.27% | -9.15% | -3.90% | -4.61% | Upgrade
|
EBITDA | 138.68 | 221.76 | 238.89 | 235.68 | 192.8 | Upgrade
|
EBITDA Margin | 8.53% | 12.37% | 16.96% | 20.41% | 17.11% | Upgrade
|
D&A For EBITDA | 70.75 | 69.19 | 62.56 | 56.72 | 24.55 | Upgrade
|
EBIT | 67.92 | 152.57 | 176.32 | 178.96 | 168.25 | Upgrade
|
EBIT Margin | 4.18% | 8.51% | 12.52% | 15.50% | 14.93% | Upgrade
|
Effective Tax Rate | 33.65% | 27.39% | 13.59% | 17.67% | 26.01% | Upgrade
|
Revenue as Reported | 1,688 | 1,816 | 1,433 | 1,172 | 1,135 | Upgrade
|
Advertising Expenses | - | 14.37 | 6.83 | 4.6 | 0.57 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.